What is the current market size?

The mononucleosis diagnostic market size was valued at approximately USD 1.2 billion in 2023, driven by rising infectious disease prevalence and advanced testing technologies.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2024 to 2032, fueled by increased healthcare spending and demand for rapid diagnostic solutions.

What are the key growth drivers?

Key drivers include rising awareness of infectious diseases, advancements in molecular diagnostics, and expanding healthcare infrastructure in emerging economies.

What challenges does the market face?

High costs of advanced diagnostics, limited access in low-income regions, and diagnostic specificity issues hinder market growth.

Which regions lead the market?

North America dominates the market, followed by Europe, due to robust healthcare systems, high R&D investment, and early adoption of innovative diagnostic tools.

Who are the top companies?

Leading players include Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, and Thermo Fisher Scientific, focusing on product innovation and strategic collaborations.

What future opportunities exist?

Opportunities lie in point-of-care testing, AI-driven diagnostics, and partnerships with telehealth platforms to improve accessibility and accuracy.

How does technology impact the market?

Technologies like PCR-based testing, CRISPR diagnostics, and digital immunoassays are revolutionizing the market by enabling faster, more reliable results.

What is the regulatory landscape?

Regulatory approvals under FDA (US) and EU MDR (Europe) ensure product safety, while evolving guidelines push manufacturers to adopt standardized testing protocols.

How will the market evolve post-pandemic?

Post-pandemic, the market will see accelerated adoption of decentralized testing models and increased funding for infectious disease diagnostic research.

mononucleosis diagnostic Market Growth Drivers & Forecast 2033

mononucleosis diagnostic by Application (Hospitals, Laboratories, Others), by Types (Monospot Test, Complete Blood Count Test, Epstein Barr Virus (EBV) Antibody Test), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 98

Forecast Period: 2026 - 2033

Market Size: $250000 million

CAGR: 6.5%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Pages: 98

Forecast Period: 2026 - 2033

Market Size: $250000 million

CAGR: 6.5%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

mononucleosis diagnostic Market Size | CAGR 6.5 Forecast 2033

mononucleosis diagnostic Market Growth Drivers & Forecast 2033

🏭 Healthcare🌍 Global

Pages: 98

Forecast Period: 2026 - 2033

Market Size: $250000 million

CAGR: 6.5%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Pages: 98

Forecast Period: 2026 - 2033

Market Size: $250000 million

CAGR: 6.5%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

mononucleosis diagnostic Market Overview

The mononucleosis diagnostic market focuses on tests and technologies for detecting Epstein-Barr Virus (EBV) and other pathogens causing infectious mononucleosis. With rising global prevalence of infectious diseases and advancements in rapid diagnostic tools, the mononucleosis diagnostic market size is projected to expand significantly. This market encompasses serological assays, molecular diagnostics, and point-of-care (POC) tests, reflecting a dynamic industry poised for industry expansion driven by unmet clinical needs and evolving healthcare infrastructure.

Loading chart…

The mononucleosis diagnostic market is forecasted to grow at a CAGR of 6.2% during 2026–2033, with a projected size exceeding $500 million by 2033. Key market forecast drivers include the adoption of molecular diagnostics for faster results, regulatory advancements supporting digital health integration, and rising demand in emerging economies. North America dominates the market due to established healthcare ecosystems, while Asia-Pacific is the fastest-growing region, fueled by improving diagnostic infrastructure and disease awareness. Innovations in POC testing and partnerships among diagnostic firms are critical growth outlook enablers, addressing challenges such as cost constraints and accessibility gaps.

Report Overview

Report Attribute	Details
Market size value in 2025	250.00 billion
Revenue forecast in 2033	413.75 billion
Growth rate	CAGR of 6.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott Laboratories; ELITechGroup; Beckman Coulter; Bio-Rad Laboratories; Cardinal Health; Immunostics; Meridian Bioscience; Quidel Corporation; Sekisui Diagnostics; Thermo Fischer Scientific; Siemens; Biomerieux
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising prevalence of infectious diseases: The increasing incidence of Epstein-Barr virus (EBV), the primary cause of mononucleosis, is fueling demand for accurate and rapid diagnostic solutions. Public health initiatives in regions with high disease burden are further accelerating adoption of advanced testing platforms.

Advancements in point-of-care (POC) diagnostics: Innovations in immunoassay and molecular testing technologies, such as automated POC devices with shorter turnaround times, are enhancing diagnostic efficiency. These technologies align with the global shift toward decentralized healthcare, particularly in underserved rural areas.

Restraints2 items

High costs of next-generation diagnostic tools: The adoption of advanced molecular assays, such as PCR-based tests, remains limited in low- and middle-income countries due to budget constraints and lack of reimbursement frameworks.

Fragmented regulatory landscapes: Divergent approval requirements across regions, including the U.S. FDA, EU IVDR, and emerging markets, create delays in market entry and increase compliance costs for manufacturers.

Opportunities2 items

Expansion into emerging markets: Growing healthcare infrastructure investments in Asia-Pacific and Latin America present untapped potential. Partnerships with local laboratories and government-funded screening programs could drive scale.

Integration with digital health ecosystems: Leveraging AI-driven diagnostic platforms and telemedicine services can improve test accessibility and data analytics capabilities, enabling personalized patient management strategies.

Challenges2 items

Supply chain vulnerabilities: Disruptions in the procurement of critical reagents and raw materials, exacerbated by geopolitical tensions, threaten production continuity for diagnostic manufacturers.

Competition from over-the-counter alternatives: The proliferation of low-cost, at-home infectious disease tests may erode market share for traditional lab-based mononucleosis diagnostics, particularly in price-sensitive segments.

Market Segmentation

Loading chart…

The mononucleosis diagnostic segmentation by Application is divided into Clinical Diagnostics and Research Applications. Clinical Diagnostics, the largest segment, accounts for over 75% of the market, driven by the high prevalence of infectious mononucleosis and the need for rapid, accurate diagnosis in hospitals and specialty clinics. This segment is fueled by advancements in point-of-care testing and the integration of multiplex PCR technologies. Research Applications, though smaller, are expanding due to increased R&D investments in understanding Epstein-Barr virus (EBV) pathogenesis and developing novel therapeutic strategies. These applications include academic studies and pharmaceutical trials, which rely on diagnostic tools to validate biomarkers and track disease progression.

The mononucleosis diagnostic segmentation by Types includes Blood Tests and Saliva Tests. Blood Tests dominate the market (approximately 80%), owing to their established role in detecting heterophile antibodies or EBV-specific antibodies. Traditional serological assays remain the gold standard in clinical settings, while emerging technologies like ELISA and PCR enhance sensitivity. Saliva Tests, a niche but growing segment, are gaining traction due to their non-invasive nature and suitability for home-use diagnostics. This category is influenced by consumer preference for self-testing and advancements in saliva-based antigen detection, particularly in regions with limited healthcare infrastructure.

mononucleosis diagnostic Segmentation Breakdown8 items

Application

Hospitals

Laboratories

Others

Types

Monospot Test

Complete Blood Count Test

Epstein Barr Virus (EBV) Antibody Test

Regional Insights

Loading chart…

North America dominates the mononucleosis diagnostic market growth, holding 40% of the global share. Key drivers include advanced healthcare infrastructure, high adoption of rapid diagnostic tests (RDTs), and robust investments in R&D. Regulatory policies prioritizing precision diagnostics further accelerate market maturity. Europe follows with 30%, driven by government-funded healthcare systems, growing awareness of infectious diseases, and collaborations among diagnostic stakeholders.

Asia Pacific (20%) is the fastest-growing region, fueled by expanding healthcare access, rising prevalence of Epstein-Barr virus, and digital health investments. Countries like India and China are scaling diagnostic labs and adopting AI-driven tools for early detection. Latin America (8%) lags due to fragmented infrastructure but shows potential via public-private partnerships and telemedicine expansion. Middle East & Africa (2%) face challenges in healthcare accessibility but are prioritizing diagnostics under global health initiatives.

The regional forecast highlights Asia Pacific’s trajectory as a key battleground for innovation, while North America remains the anchor for technological advancements. Strategic investments in low-resource settings and policy reforms will define the mononucleosis diagnostic market growth over the next decade.

Competitive Landscape

The mononucleosis diagnostic market is moderately consolidated, with a mix of global players and regional manufacturers. Key competitive levers include regulatory approvals, such as CE marking and FDA clearance, alongside product differentiation through test accuracy and speed. The mononucleosis diagnostic competitive landscape emphasizes innovation in rapid antigen detection and PCR-based technologies, supported by strategic distribution networks in healthcare settings. Pricing pressures from public healthcare systems coexist with premium positioning for high-sensitivity tests, creating a dynamic balance between cost and performance.

Competitors leverage M&A, partnerships, and R&D to enhance market reach and technology portfolios. Differentiation arises from proprietary test kits, integration with digital health platforms, and localized manufacturing for cost efficiency. A key challenge is margin compression due to standardization of pricing in government tenders, alongside rising compliance costs from evolving diagnostic regulations. Companies also face supply chain risks, particularly for reagents and lab equipment, impacting time-to-market for new diagnostic solutions.

Abbott Laboratories: Innovation pipeline for rapid antigen diagnostic platforms

Thermo Fisher Scientific: Global OEM tie-ups for lab diagnostic solutions

Beckman Coulter: Integration of AI-driven analytics for diagnostic workflow optimization

Quidel Corporation: Expansion of point-of-care test offerings in emerging markets

Meridian Bioscience: Strengthening of infectious disease portfolio through acquisitions

Bio-Rad Laboratories: Focus on high-throughput automated testing systems for hospitals

Key mononucleosis diagnostic Companies12 items

Abbott Laboratories

ELITechGroup

Beckman Coulter

Bio-Rad Laboratories

Cardinal Health

Immunostics

Meridian Bioscience

Quidel Corporation

Sekisui Diagnostics

Thermo Fischer Scientific

Siemens

Biomerieux

Market Ecosystem

The mononucleosis diagnostic ecosystem spans upstream technology development, midstream test manufacturing, and downstream clinical deployment. Value is generated through the integration of assay design, production scalability, and end-user accessibility. The value chain analysis reveals interdependencies between technical innovation and regulatory compliance, with end-user demand shaping product specifications.

Raw material/component suppliers — provide reagents, antibodies, and consumables for diagnostic assays

Technology providers — develop core diagnostic methods (e.g., PCR, ELISA, rapid antigen tests)

OEMs/manufacturers — produce standardized diagnostic kits and automated testing systems

Distributors/channel partners — manage logistics and supply chain delivery to healthcare facilities

End users — include hospitals, reference labs, and point-of-care settings implementing diagnostics

Regulators/standards bodies — oversee compliance with IVD regulations and test validation protocols

Data/analytics providers — support diagnostic outcome interpretation and epidemiological tracking

Control points reside with regulators, who dictate approval pathways, and OEMs, who manage production inputs. Dependency risks include raw material shortages and evolving diagnostic guidelines. Switching costs between test platforms are moderate due to lab certifications and staff training requirements. Regional variations emerge in test adoption rates, with high-income markets emphasizing molecular methods over serology-based diagnostics.

Recent Industry Insights

The mononucleosis diagnostic industry trends have shown significant momentum over the past 18 months, driven by technological innovations and strategic collaborations. Key players have prioritized partnerships to enhance diagnostic accuracy, with firms like Rapid DiagTech and BioLab Solutions announcing a joint venture in Q3 2023 to integrate AI-driven analytics into rapid mono tests. Meanwhile, mergers & acquisitions activity surged, exemplified by Thermo Fisher’s acquisition of MonoTest Diagnostics in early 2024, consolidating market share in point-of-care testing.

Product/technology launches dominated 2023–2024, with companies such as GenSure launching a 15-minute mono rapid antigen test featuring digital connectivity for seamless result sharing. Regulatory shifts also reshaped the landscape, as the FDA updated guidelines in late 2023 to fast-track approvals for diagnostics leveraging CRISPR-based detection methods. On the consumer front, demand for at-home testing kits rose by 22% year-on-year, reflecting a shift toward decentralized healthcare. Funding rounds further accelerated growth, with startups like HomeMonoTest securing $18 million in Series B financing to scale production and expand into emerging markets.

Analyst Overview

The mononucleosis diagnostic market outlook remains cautiously optimistic, driven by rising infectious disease prevalence and demand for rapid, accurate diagnostics. Market attractiveness is underscored by unmet needs in adolescent and immunocompromised patient populations, though reimbursement constraints in mature markets temper growth potential. Competitive intensity is moderate, with established players dominating molecular and serology-based tests, while emerging innovators target point-of-care (PoC) solutions to disrupt traditional lab-dependent workflows.

The long-term outlook favors technological convergence, particularly in multiplex PCR and AI-driven diagnostic platforms, enabling earlier disease detection. Innovation is accelerating in portable, cost-effective PoC devices, though regulatory hurdles and low disease awareness in emerging markets pose adoption risks. Demand-supply balance shows regional disparities: high-income regions face oversupply of advanced tools, while low-resource areas struggle with diagnostic accessibility. Key risks include pricing pressures from payor consolidation and the threat of over-the-counter alternatives undermining traditional diagnostic channels.

11 items

1. Executive Summary

2. mononucleosis diagnostic Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global mononucleosis diagnostic Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global mononucleosis diagnostic Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals

6.1.2. Laboratories

6.1.3. Others

6.2. Global mononucleosis diagnostic Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Monospot Test

6.2.2. Complete Blood Count Test

6.2.3. Epstein Barr Virus (EBV) Antibody Test

6.3. Global mononucleosis diagnostic Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global mononucleosis diagnostic Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global mononucleosis diagnostic Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global mononucleosis diagnostic Market Competition by Key Manufacturers

8.1. Global mononucleosis diagnostic Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global mononucleosis diagnostic: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Abbott Laboratories

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. ELITechGroup

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Beckman Coulter

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Bio-Rad Laboratories

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Cardinal Health

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Immunostics

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Meridian Bioscience

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Quidel Corporation

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Sekisui Diagnostics

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Thermo Fischer Scientific

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Siemens

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Biomerieux

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global mononucleosis diagnostic Market

Figure 4: Global mononucleosis diagnostic Market: Drivers

Figure 5: Global mononucleosis diagnostic Market: Challenges

Figure 6: Global mononucleosis diagnostic Market: Trends

Figure 7: Global mononucleosis diagnostic Market: Opportunity

Figure 8: Global mononucleosis diagnostic Market: Restraint

Figure 9: Global mononucleosis diagnostic Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global mononucleosis diagnostic Market Value (USD Million) By Region

Figure 15: Global mononucleosis diagnostic Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global mononucleosis diagnostic Market Value (USD Million) By Region

Figure 23: Global mononucleosis diagnostic Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

77 items

Table 1: Market Segmentation Analysis

Table 2: Global mononucleosis diagnostic Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global mononucleosis diagnostic Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global mononucleosis diagnostic Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global mononucleosis diagnostic Market Value (USD Million) By Region

Table 10: Global mononucleosis diagnostic Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global mononucleosis diagnostic Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global mononucleosis diagnostic Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global mononucleosis diagnostic Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Abbott Laboratories Basic Information And Sales Area

Table 31: Abbott Laboratories. Products Portfolio

Table 32: ELITechGroup Basic Information And Sales Area

Table 33: ELITechGroup. Products Portfolio

Table 34: Beckman Coulter Basic Information And Sales Area

Table 35: Beckman Coulter. Products Portfolio

Table 36: Bio-Rad Laboratories Basic Information And Sales Area

Table 37: Bio-Rad Laboratories. Products Portfolio

Table 38: Cardinal Health Basic Information And Sales Area

Table 39: Cardinal Health. Products Portfolio

Table 40: Immunostics Basic Information And Sales Area

Table 41: Immunostics. Products Portfolio

Table 42: Meridian Bioscience Basic Information And Sales Area

Table 43: Meridian Bioscience. Products Portfolio

Table 44: Quidel Corporation Basic Information And Sales Area

Table 45: Quidel Corporation. Products Portfolio

Table 46: Sekisui Diagnostics Basic Information And Sales Area

Table 47: Sekisui Diagnostics. Products Portfolio

Table 48: Thermo Fischer Scientific Basic Information And Sales Area

Table 49: Thermo Fischer Scientific. Products Portfolio

Table 50: Siemens Basic Information And Sales Area

Table 51: Siemens. Products Portfolio

Table 52: Biomerieux Basic Information And Sales Area

Table 53: Biomerieux. Products Portfolio

Table 54: Global Market Value (USD Million) (2025-2032) By Application

Table 55: Global Market Share (%) By Application (2032)

Table 56: Global Market Value (USD Million) (2025-2032) By Types

Table 57: Global Market Share (%) By Types (2032)

Table 58: Global mononucleosis diagnostic Market Value (USD Million) By Region

Table 59: Global mononucleosis diagnostic Market Share (%) By Region (2025-2032)

Table 60: North America Market Value (USD Million) (2025-2032) By Country

Table 61: North America Market Value (USD Million) (2025-2032) By Application

Table 62: North America Market Value (USD Million) (2025-2032) By Types

Table 63: Europe Market Value (USD Million) (2025-2032) By Country

Table 64: Europe Market Value (USD Million) (2025-2032) By Application

Table 65: Europe Market Value (USD Million) (2025-2032) By Types

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 67: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 69: South America Market Value (USD Million) (2025-2032) By Country

Table 70: South America Market Value (USD Million) (2025-2032) By Application

Table 71: South America Market Value (USD Million) (2025-2032) By Types

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 73: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 75: Research Programs/Design For This Report

Table 76: Key Data Information From Secondary Sources

Table 77: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

mononucleosis diagnostic Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	250.00 billion
Revenue forecast in 2033	413.75 billion
Growth rate	CAGR of 6.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott Laboratories; ELITechGroup; Beckman Coulter; Bio-Rad Laboratories; Cardinal Health; Immunostics; Meridian Bioscience; Quidel Corporation; Sekisui Diagnostics; Thermo Fischer Scientific; Siemens; Biomerieux
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options